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Abstract
A few years ago, the prevention of anti-D immunization was currently based on systematic postnatal prophylaxis
associated with targeted antenatal injection in high-risk situations of foeto-maternal haemorrhage. The failures of
prevention are mainly due to the non-respect of established guidelines for RhIG prophylaxis, and to spontaneous
undetected foetal-maternal haemorrhages without any obvious cause during the third trimester of pregnancy.
In order to reduce the rate of residual post-pregnancy anti-D immunization, several countries decided to associate
the classical prophylaxis to a routine antenatal anti-D prophylaxis (RAADP) during the 28th or 29th week of
gestation. Since about ten years, the foetal RHD genotyping in maternal plasma enables us to limit the antenatal
prophylaxis only to those D- women carrying a D+ foetus.
This paper deals with: the advantages of an antenatal prevention in the light of non invasive foetal RHD
genotyping, the rules rendering prevention protocols efficient whatever the algorithm applied, and the recommended
immuno-haematology follow-up of women who have received RhIG.
Keywords: Anti-D prophylaxis; Foetal RHD genotype; Haemolytic
Disease of the foetus and Newborn
Introduction
The pathogenesis of haemolytic disease of the foetus and newborn
(HDFN) was first elucidated by Levine (1941) thanks to the discovery
of the Rh (Rhesus) blood group by Landsteiner and Wiener in 1940
[1,2]. He demonstrated the possibility of maternal immunization
through placenta against foetal antigen(s) inherited from the father
and lacking in the mother; in this particular case, the D antigen.
In 1940, prenatal mortality due to HDFN was around 4 out of 100
births, representing 10 percents of the global childhood mortality. Half
of the affected foetuses died from hydrops foetalis or nuclear icterus.
The improvement of the management of this pathology by experts
reduced the mortality rate to less than 5 percent. The
immunoprophylaxis of anti-D immunisation by injection of anti-D
immunoglobulin’s at delivery was only introduced in the late sixties
[3].
Despite the application of this immuno-prophylaxis to RhD
negative patients, HDFN due to anti-D still remains today the most
frequent and severe in Europe [4].
In the absence of anti-D injection, a D negative mother bearing an
ABO compatible D positive foetus has a 16% possibility of developing
alloimmune anti-D. When the mother and the foetus are ABO
incompatible (20% of pregnancies), this rate falls to 2%. So, globally,
the risk for a D-negative woman to become immunized by a D-
positive foetus stands at around 13.2% [3].
However, when appropriate doses of anti-D immunoglobulin’s are
injected within 72 hours after delivery, the rate of immunisation is
reduced by 90% and the residual risk is around 1 to 2% [5].
Most failures are due on one hand, to undetected foeto-maternal
haemorrhages (FMH) that occurs during the third trimester of
pregnancy, and, on the other hand, (in more than 30% of cases), to
disregard for prophylaxis rules [6].
When D negative patients are systematically injected at 28 weeks of
pregnancy, the residual risk is further reduced by more than 60% [7].
Throughout pregnancy, foeto-maternal haemorrhage increases in
frequency (from 3% during the first trimester to 45% during the third
one), and in volume (<0.1 mL during the first trimester and in variable
amounts during the third one) [8]. A dose-dependant correlation is
known to exist between the volume of foeto-maternal haemorrhage
and the occurrence of allo-immunisation. This is the reason why an
adequate and timely administration of anti-D immunoprophylaxis
remains essential. These practical aspects, including guidance
regarding to routine antenatal anti-D prophylaxis (RAADP), are
reviewed in this paper.
Systematic Antenatal Prophylaxis
Cost/efficiency
Prevention of anti-D allo-immunisation can be applied following at
least two different approaches: the first one, as a postnatal prophylaxis
after delivery of a Rh D positive baby, in addition with targeted
prophylaxis following potentially sensitizing events during pregnancy,
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and the second one, as a systematic antenatal prophylaxis at 28 weeks
of gestation.
This matter has been discussed in a review published by Parant,
who concluded that in the group without systematic antenatal
prophylaxis, the global rate of immunisation turned around 1.5% (1.2
to 1.9%), whereas in the group of patients who benefited from a
systematic antenatal prophylaxis, the average rate of allo-
immunization was around 0.3% (0 to 0.9%) [9]. These data are in
favour of sytematic prevention at 28-29 weeks of gestation [10].
From an economical point of view, Canadian and English studies
tend to show that systematic prevention involves greater drug and
administrative costs than the targeted ones, but the cost/efficiency
ratio still remains favourable [11]. The benefits of RAADP to be
considered include: avoidance of anti-D sensitisation, reduction of
incidence of haemolytic diseases, reduction of foetal/neonatal losses,
avoidance of disability of the child, and positive effects of these
outcome measures on the quality of life of the mother [12]. Most
western countries recommend a systematic antenatal prophylaxis for
all Rh D negative patients. However, so far, none of these studies ever
organized an antenatal prevention which would be dedicated solely to
those women bearing Rh D+ foetus. This eventuality is now rendered
possible owing to the determination of foetal RHD from maternal
plasma. It allows us to reduce, by around 40%, the cost of unnecessary
RhIG prenatal injections. This genotyping approach may offer
additional cost benefits by reducing the immuno-haematological and
sonographic follow-up of pregnancy [13]. The cost-effectiveness
calculations of this approach will depend on the cost of foetal
genotyping in maternal plasma. At present, this test is not refunded by
the Health Service in Belgium except in anti-D alloimmunized
mothers.
Search for RHD foetal gene from maternal plasma
Since 2002 in our hospital, the determination of foetal RHD from
maternal plasma has been included in the biological follow-up of Rh D
negative patient as early as the 12th week of gestation. We have
reported 100% diagnostic accuracy in our non invasive foetal RHD
genoyping assay by targeting multiple exons with real-time PCR
[14,15]. The overall diagnostic accuracy was 96.5% (95% CI: 95.6-97.2)
in the meta-analysis of Geifman-Holtzman, several studies also
showing 100% diagnostic accuracy [16].
In order to avoid reporting a false negative result, the Y-
chromosome linked SRY gene sequence is amplified to confirm that
foetal DNA is present in maternal plasma. A positive PCR signal
ensures that the foetal DNA is present. This SRY-based internal
control is only applicable for pregnancies carrying a male foetus. So,
when the search for foetal RHD is negative and SRY gene absent, it is
recommended to confirm the first result by using either a new blood
sample a few weeks later or amniocytes when an amniotic liquid
puncture has been programmed for another reason. This careful
approach is justified by the absence of internal control for the Rh D
negative female foetuses. It does not significantly differ from the basic
rules in the matter of ABO/D blood groups that require two different
determinations before being validated.
The knowledge of foetal RHD status allows us to save up the
injection of anti-D immunoglobulins at 28-29 weeks as well as those
applied in the situations at risk of FMH among the 40% of Rh D
negative women bearing an RHD negative foetus.
On the other hand, genotyping of the foetal D gene also exempts D
negative patients, bearing a D- foetus, to be exposed to any risk that
might be associated with the administration of a human plasma-
derived product. Moreover, there is worldwide shortage of anti-D [17].
As far as the post-partum immunoprophylaxis is concerned,
determining the Rh D phenotype of a newborn from a D negative
woman must continue to be determined even when the RHD foetal
genotype has been searched during gestation [18].
Because samples collected in operating rooms are frequently
mislabelled (newborn/mother inversion, cord blood contaminated by
maternal blood , requisition mismatches), the French Society of Blood
Transfusion (as well as the Society of Perinatal Medicine in France)
recommends confirming the D negative phenotype of the baby
determined on cord blood, by a second one performed on peripheral
blood [19]. This should be strongly recommended when there was no
previous RHD genotyping of the foetus during the pregnancy.
Rules of Good Practice
Indications
D negative women: Prophylaxis concerns all non immunized D
negative women during and at the end of gestation. It has therefore no
effect and is perfectly useless on previously immunized women. In rare
cases of very weak anti-D which are solely detected by ultra sensitive
techniques (enzymes) but remain undetectable by the anti-human
globulin assay (AHG) in gel phase, the relevancy of prophylaxis must
be discussed for each case individually. Usually, the follow-up in time
allows us to decide the best approach.
Weak D women (previously named Du): The term weak D (Du) is
used to design a weakened expression of a “complete” D antigen
(Figure 1). The molecular characteristic of the weak D types is single
missense mutations which produce amino-acid exchange in the
intracellular or transmembrane region of the D antigen [20]. The
molecular techniques to predict foetal D status using maternal plasma,
don’t detect maternal weak D types and the maternal RHD gene
appears “intact” as in D+ patients. The lower immunoreactivity of D
antigen requires the indirect antiglobulin technique (IAT) for
detection. However, at present time, most weak D are now detected by
direct agglutination using monoclonal IgM anti-D reagents, or in the
gel matrix technique and are considered as D positive [21]. The
majority (90%) of caucasian individuals presenting a weak D
phenotype are weak types 1, 2, 3. Among European persons, these
weak D types are always associated with the DCe or the DcE
haplotypes. They cannot so far be anti-D immunized. Therefore these
patients have to be treated as D positive, i.e.: transfused with D positive
red cells and, following delivery of a D positive baby, not given anti-D
immunoglobulin [22,23].
Partial D women: The term partial D is used to refer to an
incomplete D antigen in which some extracellular epitopes are missing
(Figure 1). Partial D phenotypes are the results of gene rearrangements
and/or senseless mutations in regions of RHD encoding portions of D
protein external to the red cell membrane [20]. Individuals with a
partial D phenotype can produce anti-D when they are exposed to D
positive red blood cells (RBC). Therefore, it is advisable that they
should be typed as D negative if they are candidates for transfusion or
anti-D prophylaxis. Such a strategy is applied in our laboratories to
type partial DVI, the most frequent D partial phenotype amongst
white people. DVI presents also a weak expression of D and their
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carriers may be readily anti-D immunized [24]. In practice, most other
partial D are usually classified as D positive in direct agglutination
tests with currently available reagents and can often only be identified
as having partial D antigen after and because they have produced anti-
D.
Figure 1: The genetic background for different RhD types
(simplified). D negative Caucasians most often have a complete
RHD gene deletion, but Africans and Asians have often an inactive
RHD. The partial D red blood cells (RBC) demonstrate a normal
number of Rh D antigens but with altered D epitopes. Many partial
D results from hybrid genes with portions of RHD replaced by the
corresponding portions of RHCE. The weak D red blood cells have
a reduced number of complete D antigens. Weak D types primarily
results from single point mutations in RHD. Some partial D (the
most common in Caucasians: DVI) show both weak D and partial
D features.
Pregnant women with suspected partial D or Weak D and
molecular foetal RHD typing: Because some weak D expression
reflects the presence of a partial D and because some carriers of rare
weak D types may become immunized, the guidelines for prenatal and
perinatal immunohaematology (edited by AABB) say that the weak D
test by IAT should not be used to D type maternal samples [25].
Therefore, these patients with a weak expression of D are classified as
D- and receive D- transfusion and RhIG prophylaxis. So, obstetricians
send us some apparent D- women for foetal RHD genotyping. But
molecular foetal RHD typing with maternal plasma should uncover a
maternal “intact” RHD gene in some of these apparently D- women
and the risk of erroneously defining the RHD gene as being of foetal
origin should be considered [15]. Discrepancies between maternal D-
phenotype and a maternal RHD+ genotype can create confusion in
obstetricians’ mind. On the other hand, our molecular techniques
using maternal plasma detect the most of partial D with radical
changes of the RHD gene. For these reasons, we now systematically
test for weak D by IAT all D- women who are referred for foetal RHD
genotyping and perform, from a maternal buffycoat DNA, a RHD
genotyping of serologically D-, C+, and/or E+ European pregnant
women. Those molecular tests distinguish common partial and weak
D types and enable us not to give RhIG prophylaxis to pregnant
women carrying prevalent weak D types 1, 2 and 3. The partial D and
other no types 1 to 3 weak D patients would be immunized when
exposed to D+ blood. In this case, injection of anti-D immunoglobulin
in pregnant women is proposed althought its efficiency in preventing
sensitization has not been demonstrated.
Among European populations, about one percent of people carry
variant RHD alleles producing weak D including some partial D
[26,27]. In Black individuals, most D variants with a weak expression
are partial D and are often associated with Dce haplotype [28].
Weak D baby: All serologically D negative babies should be tested
for the presence of weak D expression with the indirect antiglobulin
technique. If the baby is weak D, prophylaxis must be applied to D
negative women, whereas it’s not necessary if the baby is proven to be
D negative.
Detection of foetal erythrocytes
The principle of the Kleihauer-Betke assay - the most widely used in
Belgium - lies on the greater resistance to acid elution of foetal
hemoglobin (HbF) compared to adult hemoglobin (HbA). In practice,
HbA is eluted from RBCs fixed on blood films, leaving red cell ghosts,
so that the red cells containing HbF can be stained.
The volume of foetal RBC is calculated according to the following
formula [29]:
Volume of foetal RBC = 2400 × F/A mL,
where F/A is the proportion of foetal (F) RBC among maternal
adult (A) RBC.
- 2400 = 1800 x 1.22 × 1.09 mL
- 1800 mL = volume of maternal red blood cells,
- 1.22 = foetal RBC are 22% larger than adult RBC,
- 1.09 = 92% = proportion of foetal RBC stain darkly.
The volume of foetal blood (assuming a haematocrit of 50%) can be
deduced by multiplying the volume of foetal RBC by two.
Clinicians should be aware that the results of a Kleihauer-Betke test
can be expressed on laboratory protocols either in terms of mL of
fœtal RBC or in mL of fœtal whole blood. This is particularly
important when the dose of anti-D immunoglobulins has to be
adjusted according to the volume of the FMH. The general principe is
that 100 µg of RhIG is capable of suppressing sensitization by 4-5 ml of
foetal RhD positive red blood cells or by 8-10 ml of foetal RhD positive
whole blood.
The Kleihauer test’ sensitivity allows to detect 7.2 mL of foetal RBC
in the maternal circulation i.e. around 0.3% of fœtal RBC, with a
variation coefficient of around 10%.
Some hemoglobinopathies (thalassemia, drepanocytosis, and
hereditary persistence of foetal hemoglobin…) present varying
resistance to acid elution and may entail false positive results. When
such a case is suspected, some laboratories detect D positive foetal
RBC by flow cytometry, by using fluorochrome coupled anti-D
reagents. Flow cytometry presents a very high sensitivity (0.01 % i.e.
0.2 mL of foetal RBC), but this method is expensive, time consuming
and not suitable for emergency cases.
At delivery or in situations at risk of FMH, prophylaxis must always
be applied even when the result of the Kleihauer test is negative.
In practice, the search for foetal RBC should be performed within 2
hours of delivery (or a high-risk situation) but at least 30 minutes after
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placental evacuation to be sure that all the foetal erythrocytes have
entered in maternal circulation [30].
Kleihauer’s test results should always be transmitted to the clinician
for those cases necessitating a supplementary dose, which should be
administered within 72 hours post-delivery.
Doses
In Belgium, there is only one preparation of anti-D
immunoglobulin (RhIgG) available (Rhogam): it contains 300 µg/mL
of IM injectable RhIgG. 300 µg is an amount of IgG capable of
neutralizing 12 to 15 ml of foetal RBC (i.e. 24 to 30 mL of foetal
blood).
The routine antenatal anti-D prophylaxis consists of injecting 300
µg of anti-D at between 28 and 29 weeks of gestation.
After invasive examinations or accidents occurring before the 20th
week, one IM dose is sufficient since the blood mass of a 20 weeks old
foetus is lower than the volume neutralized by 300 µg.
After 20 weeks, there is a need to assess the volume of FMH and the
dosage should be adapted according to the volume of circulating foetal
RBC: 10 µg per 0.5 mL foetal RBC or 1 mL foetal blood.
When the risk of FMH is low, for example after extra-placenta
amniocentesis, it is not necessary to perform a Kleihauer test, and
injection of one standard dose of anti-D is sufficient.
It is recommended to search for irregular antibodies (RAI) before
the first injection of anti-D prophylaxis, even if the injection can be
made before the RAI result is obtained. This allows for the detection of
any anti-D allo-immunisation (and other than anti-D) which would
have been undetectable earlier [31,32].
Delay for the injection of RhIgG
To reach optimal efficiency, the injection of RhIG should be made
as soon as possible within 72 hours following delivery or HFM. If it
has been omitted, injection of RhIgG can still be performed until 28
days after delivery, but the later it is done, the less efficient it will be
[33].
Control of RhIG efficiency
The sole relevant control test is the search for foetal RBC in
maternal blood 48 hours after injection of RhIG [10]. RhIG has been
efficient when all foetal RBC have disappeared. This control is only
necessary when a supplementary dose has to be injected i.e. when the
foetal hemorrhage was greater than 15 mL of foetal RBC.
There are no arguments at all to say that the presence of passive
anti-D in maternal circulation can be considered as reflecting the
efficiency of RhIG injection; it only reflects the fact that the injection
has really been made.
Within three to seven days after IM injection of RhIG, the titre of
anti-D in maternal blood can reach ¼ (when measured by using the
reference method i.e. IAT in saline). Antibody titration decreases
thereafter as a function of both the half-life time of IgG (21 days), and
the rate of consumption by D positive foetal RBC. However, a residual
activity of RhIG can be demonstrated in some maternal plasma during
several months.
If any doubt remains concerning the appropriate dosage of RhIgG
administered, the clinician can register the situation in the light of
both the results of the Kleihauer test and the presence of anti-D in
maternal blood (Table 1). Absence of detectable anti-D has –





D* in maternal blood
Action
0 No 2nd Injection
0 Yes No 2nd injection
Yes No Assess FMH
Inject appropriate dose
Yes Yes assess FMH at 48 h
*IAT tube method in phosphate buffered saline
Table 1: After an initial injection of RhIG, when a second one should
be injected?
One should also keep in mind that several factors can affect the
clearance of fetal RBC, including: a laboratory failure at the time of the
initial foetal RBC count, a dizygotic twin pregnancy with one D
positive and one D negative foetus, a weak D expression or a
splenectomized woman [34].
Finally, so many different situations exist - which can entail error,
omission or default - that it is more reasonable to promote a
systematic injection of RhIgG at delivery even when the patient has
already received one before.
Immuno-Haematologic Features of RhIG Injections
In maternal blood 
Residual anti-D: Sometimes, a weak anti-D activity may be detected
in maternal serum for several weeks by IAT and, by more sensitive
techniques, for several months after RhIgG injection, and persistent
passive anti-D may mask an early active allo-immunisation. On the
other hand, the clearance of passive anti-D is highly variable from one
patient to another. Therefore, a low titration of anti-D (<¼ by IAT)
does not allow to discriminate passive and active immunisation [25].
To provide a basis for distinguishing between prophylactic and
immune anti-D, all D negative pregnant women should benefit before
the RAADP, at 28 weeks gestation, from a screening for red cell
alloantibodies. Moreover, it is essential for the biologist to be informed
to any previous administration of RhIgG in the current pregnancy,
including date and dose, at the time of analysis, in order to interpret
the anti-D titre. It is generally admitted that anti-D titration higher
than ¼ is highly predictive of an active immunisation. When titration
results are not conclusive, it is necessary to repeat the analysis a few
weeks later to be able to conclude to passive or active immunisation.
Prophylactic anti-D levels will fall with time whereas immune anti-D
levels will remain stable or rise. Some authors propose to perform
micro titration to differentiate an active from a passive anti-D in the
follow-up of RhIG prophylaxis [35].
In practice, any laboratory request form for the search for irregular
antibodies during pregnancy should indicate if the patient has or not
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received RhIG, and if so, when. Besides, injection of RhIG should
systematically be noted in the medical history of the patient even
though this is not (yet) mandatory in Belgium.
Calendar for the research of irregular antibodies during pregnancy:
In the absence of any sensitizing event or clinical indication, there is
no need to repeat an antibody screening at the 8th or 9th month when
a systematic prophylaxis, preceded by a screening for red cell
alloantibodies, has been applied at 28 weeks [36].
However, the introduction of RAADP has resulted in a positive
antibody screen with the detection of anti-D in samples taken after 28
weeks gestation. A panel of D negative cells should be used to exclude
the presence of unexpected alloantibodies of other specificities. If the
mother needs blood transfusion in a context of obstetrical
haemorrhage in the delivery, this would lengthen the delay before
blood product can be delivered. Therefore to ensure an appropriate
blood management of obstetrical haemorrhage, which are often
sudden and unexpected, a search for irregular antibodies can be
suggested within the 7 days preceding delivery in order to identify
alloantibodies other than pass if anti-D possibly present in the serum
of the mother [37,38]. In presence of clinically relevant alloantibodies,
a compatibility testing must be performed [39].
Hindrances
Plasma used to prepare anti-D immunoglobulins is of human
origin; they are collected from immunized blood donors and therefore
may contain Rhesus antibodies other than anti-D: anti-C or anti-E, for
example. That is the reason why it may occur that anti-C or anti-E be
detected in the serum of injected women [34].
In the newborn 
Anti-D prenatal prophylaxis has no effect on the foetus. At most,
foetal red blood cells can be sensitized, which will lead to a positive
direct Coombs test at birth, but without any clinical consequences
[40]. However, if multiple doses are given, it is recommended that
bilirubinemia should be followed.
Conclusion
The possibility to know the RHD foetal genotype from a maternal
blood sample during pregnancy should dramatically modify the
recommendations in the matter of prophylaxis for foetal-maternal
allo-immunization.
Associated with the routine antenatal anti-D prophylaxis at 28-29th
week of gestation, it is possible now to propose a new approach of D
negative pregnant women (Figure 2).
RHD foetal genotyping during pregnancy allows us to recommend
a prevention policy targeted at the 61% of D- women bearing a D+
foetus, by systematically injecting anti-D immunoglobulin during the
third trimester of pregnancy. At the same time, knowing the RHD
foetal status allows to avoid injections in 39% of women carrying a D-
foetus.
It is highly regrettable to see that prevention failures are mainly due
to human or functional negligence: default of injection, too late
injection, and so on.
At the time of accreditation, it was probably worth reminding
ourselves of the best practices for a high-risk pregnancy follow-up: the
predictive value of antibody screening, the significance of circulating
specific antibodies, the results of Kleihauer, which allows us to
measure the range of foetal-maternal haemorrhage and to adjust the
dose of RhIG to inject.
Even if any best practice rule will never replace the medical
judgement of clinicians, it should be taken into consideration how
they have progressed and benefited from technological advances such
as the foetal RHD genotyping obtained from a non invasive
examination.
Figure 2: Algorithm for RhIG prophylaxis in pregnant D- women.
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